Investors

Investors Overview

Company Profile

Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita owns a portfolio of non-prescription skincare products and has one FDA approved prescription product, Pliaglis that is licensed globally to Galderma SA and Taro Pharmaceuticals for the U.S. market. Crescita owns the sales and marketing rights in Canada and Mexico.

Stock Snapshot

Report of Organizational Actions Affecting Basis of Securities
– March 30, 2016

Crescita Share Valuation
– March 14, 2016

Recent News

• Crescita Therapeutics Inc. to Present at The MicroCap Conference on June 21st in Toronto
  Release date 2018-06-19

• Crescita Therapeutics™ Reports 2018 Third Quarter Results Strong Royalty Revenue and Achievement of First Pliaglis US Sales Milestone Positive Adjusted EBITDA of $0.8M
  Release date 2018-11-09

Transfer Agent

AST Trust Company (Canada)
P.O. Box 700, Station B
Montreal, QC
Canada  H3B 3K3
Telephone: 1-800-387-0825 or outside Canada and U.S. 416-682-3860
Fax: 1-888-249-6189 or outside Canada and U.S. 514-985-8843

Website: www.canstockta.com
Email: inquiries@canstockta.com